Name: Anticipated growth trajectory for enlarged pathology division?
Uploaded: 2022-04-05T06:24:49.044789+00:00
Duration: 1317 s
Channel: Vox Markets
Description: Anticipated growth trajectory for enlarged pathology division?

https://d3ev5earl6dvd0.cloudfront.net/public-media/videos/003/477/003477/video_f9ehW33.mp4#t=335

Vox Markets

Anticipated growth trajectory for enlarged pathology division?

Strategic rationale wrt the exciting £18.5m acquisition of LDPath in Mar'22

Progress on integration.

Opportunity to introduce AI to increase speed, throughput & capacity of existing pathologists?

Key takeaways from this morning's 2021 numbers

VAT dispute with HMRC

Future growth of Genomics & Stability Storage divisions

Opportunity to repurpose Covid PCR testing resource & equipment.

Possible new organic and M&A investments ?

Q1 trading & 2022 outlook

Indicative stock valuation

Long term target for Gross & EBITDA margins.

Future news flow

In this fascinating interview, Executive Chairman Jay Lecoque & CFO Tony Ratcliffe of SourceBio International take me through today's record results & positive outlook. Including:

1)  Strategic rationale wrt the exciting £18.5m acquisition of LDPath in Mar'22. Start
·       Progress on integration. 04:45
·       Anticipated growth trajectory for enlarged pathology division? 05:35
·       Opportunity to introduce AI to increase speed, throughput & capacity of existing pathologists? 06:30

2)  Key takeaways from this morning's 2021 numbers. 06:55
·       VAT dispute with HMRC. 08:45

3)  Future growth of Genomics & Stability Storage divisions. 09:50

4)  Opportunity to repurpose Covid PCR testing resource & equipment. 11:25

5)  Possible new organic and M&A investments ? 14:25

6)  Q1 trading & 2022 outlook. 17:10
      Indicative stock valuation. 19:10
     Long term target for Gross & EBITDA margins. 19:45

7)  Future news flow. 21:10

In this fascinating interview, Executive Chairman Jay Lecoque &amp; CFO Tony Ratcliffe of SourceBio International take me through today's record results &amp; positive outlook. Including:1) Strategic rationale wrt the exciting £18.5m acquisition of LDPath in Mar'22. Start · Progress on integration. 04:45 · Anticipated growth trajectory for enlarged pathology division? 05:35 · Opportunity to introduce AI to increase speed, throughput &amp; capacity of existing pathologists? 06:302) Key takeaways from this morning's 2021 numbers. 06:55 · VAT dispute with HMRC. 08:453) Future growth of Genomics &amp; Stability Storage divisions. 09:504) Opportunity to repurpose Covid PCR testing resource &amp; equipment. 11:255) Possible new organic and M&amp;A investments ? 14:256) Q1 trading &amp; 2022 outlook. 17:10 Indicative stock valuation. 19:10 Long term target for Gross &amp; EBITDA margins. 19:457) Future news flow. 21:10

https://d3ev5earl6dvd0.cloudfront.net/public-media/videos/003/477/003477/video_f9ehW33.mp4